Neurocrine Biosciences | NBIX - Stock


Neurocrine Biosciences reported $104.2M in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
AbbVie USD 5.13B 78M Jun/2026
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
ALKERMES USD 298.96M 37.75M Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Cytokinetics USD 380K 226K Jun/2026
Exelixis USD 26.6M 4.92M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Halozyme Therapeutics USD 137.14M 18.33M Jun/2026
Incyte USD 112.54M 3.08M Jun/2026
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Repligen USD 186.6M 7.35M Jun/2026
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Teva Pharmaceutical Industries USD 3.18B 3M Mar/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026